Share
.webp)
.webp)
.webp)
.webp)
Mandeep Kaur
Passkey Therapeutics, the developer of the Locksmith® platform for identifying novel therapeutic opportunities through synergistic drug combinations, has appointed Mandeep Kaur, MD, MS, as Chief Medical Officer (CMO).
In her new role, Dr. Kaur will lead the company’s clinical and medical strategy as Passkey advances multiple Locksmith-discovered drug combinations into clinical studies across a range of therapeutic areas.
Dr. Kaur brings extensive experience in biotechnology, clinical development, medical affairs, and regulatory strategy. She most recently served as Senior Vice President of Global Medical Affairs and Outcomes Research for Rare Disease at Amgen following its acquisition of Horizon Therapeutics, where she directed global medical strategy across a diverse portfolio of therapies.
Over the course of her career, Dr. Kaur has contributed to 19 product launches and played a key role in several major biopharmaceutical transactions. Her expertise in clinical execution, regulatory engagement, and commercialization is expected to support Passkey’s efforts to validate and advance its innovative drug combination approach.
As Chief Medical Officer, Dr. Kaur joins an experienced leadership team led by co-founders Bruce Beutel, PhD, Chief Executive Officer, and William Chen, PhD, Chief Technology Officer. Together, they are focused on accelerating the development of therapies identified through the company’s computational genetics-driven platform.
Passkey’s proprietary Locksmith platform combines insights from human genetics, biology, and pharmacology to identify combinations of approved medicines that may generate therapeutic benefits beyond those achieved by individual drugs alone. By leveraging medicines with established safety profiles, the company aims to accelerate clinical validation and rapidly explore new treatment opportunities for diseases with significant unmet medical needs.
The appointment of Dr. Kaur strengthens Passkey’s leadership as the company advances its clinical strategy and works to demonstrate the real-world potential of Locksmith-identified drug combinations across multiple therapeutic areas.
